OBJECTIVE: To probe into the therapeutic effects of Ningxinbao capsules combined with dabigatran etexilate in the treatment of non-valvular atrial fibrillation. METHODS: A total of 130 patients with non-valvular atrial fibrillation admitted into the cardiovascular medicine department of Zhangjiakou the First Hospital from Aug. 2019 to Sept. 2020 were extracted to be divided into the observation group（n=65） and the control group（n=65） via the random number table. The control group was treated with dabigatran etexilate

while the observation group was additionally given Ningxinbao capsules based on the control group. The clinical efficacy

vascular endothelial function [circulating endothelial cell（CEC）

endothelin-1（ET-1） and von Willebrand factor（vWF）]

coagulation status [activated partial thromboplastin time（APTT）

prothrombin time（PT）

fibrinogen（FIB） and thrombin time（TT）]

cardiac function indicators [left ventricular ejection fraction（LVEF）

cardiac output（CO） and cardiac index（CI）]

quality of life

embolism and bleeding risk and survival status before and after treatment were compared between two groups. RESULTS: The total effective rate of the observation group was 89.29%（50/56）

significantly higher than that of the control group（71.43%

40/56）

the difference was statistically significant（P<0.05）. The levels of CEC

ET-1 and vWF in the observation group after treatment were lower than those in the control group

the APTT

PT and TT in the observation group after treatment were significantly longer than those in the control group

yet the FIB was higher than that in the control group

LVEF

CO and CI were higher than those of the control group

the differences were statistically significant（P<0.05）. After treatment

the scores and total scores of quality of life in the observation group were significantly higher than those in the control group

the difference was statistically significant（P<0.05）. The incidence of embolism events and bleeding events in the observation group were lower than those in the control group after 6 months and 12 months of treatment

and the differences were statistically significant（P<0.05）; there was no significant difference in 12-month survival rate between two groups（P>0.05）. CONCLUSIONS: The efficacy of Ningxinbao capsules combined with dabigatran etexilate in the treatment of non-valvular atrial fibrillation is significant

which can protect the heart

reduce the damage of vascular endothelial function and coagulation function

improve the quality of life and reduce the risk of bleeding.